On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

Summary

The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.

Timeline

Start

2024-07-31

Primary completion

2025-07-31

Completion

2025-12-31

Drugs

Indications